Bio-Techne (TECH) Stock
Key stats
- Market cap
- $11.41B
- Price / Earnings ratio
- 62.7x
- EPS (TTM)
- $1.17
- Volume
- Loading
- 52-week high
- $72.83
- 52-week low
- $43.20
- Dividend yield
- 0.55%
- Dividend amount (latest)
- $0.08
- EPS vs analyst estimate
- +5.0%Q1 FY26 · $0.42 vs $0.40
Source: third-party data provider, as of November 7, 2026
EPS estimate: analyst consensus
Compare with TECH
Recent news

Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
TECH

INCY or TECH: Which Is the Better Value Stock Right Now?
INCY or TECH: Which Is the Better Value Stock Right Now?
TECH

Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
TECH

TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
TECH
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 55.73
- MACD 12/26/9
- 0.08
- EMA 9 of MACD
- 0.09
- MACD histogram
- -0.01
- SMA 50
- $72.48
- Price above SMA 50
- EMA 50
- $72.03
- Price above EMA 50
- SMA 200
- $63.21
- Price above SMA 200
- EMA 200
- $65.27
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2026Earnings
The market is expecting earnings per share of $0.39 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
Bio-Techne's Q1 Earnings on Deck: What's in Store for the Stock?
TECH

INCY or TECH: Which Is the Better Value Stock Right Now?
INCY or TECH: Which Is the Better Value Stock Right Now?
TECH

Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
Why Is Techne (TECH) Down 0.1% Since Last Earnings Report?
TECH

TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
TECH Stock Alert: Halper Sadeh LLC is Investigating Whether Bio-Techne Corporation is Obtaining a Fair Price for its Shareholders
TECH

TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
TECH Q4 Earnings Meet Estimates, Revenues Surpass, Stock Rises
TECH

Techne (TECH) Q4 Earnings Meet Estimates
Techne (TECH) Q4 Earnings Meet Estimates
TECH

Bio-Techne beats revenue estimates on research, diagnostics demand uptick
Bio-Techne beats revenue estimates on research, diagnostics demand uptick
TECH

JAZZ vs. TECH: Which Stock Is the Better Value Option?
JAZZ vs. TECH: Which Stock Is the Better Value Option?
TECH

Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?
Bio-Techne's Q4 Earnings on Deck: What's in Store for the Stock?
TECH

Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH
Bio-Techne Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Bio-Techne Corporation - TECH
TECH
News tone: automated (AI) classification of the article's content, not a price prediction.
About Bio-Techne
Bio-Techne Corporation is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. Bio-Techne’s portfolio also includes protein analysis solutions, sold under the ProteinSimple brand name, that offer researchers efficient and streamlined options for automated Western blot and multiplexed ELISA workflow. These reagent and protein analysis solutions are sold to biomedical researchers, as well as clinical research laboratories, and constitute the Protein Sciences Segment.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Kim Kelderman | CEO, President & Director | 1968 |
| Mr. James T. Hippel CPA | Executive VP of Finance & CFO | 1971 |
| Mr. Shane V. Bohnen | Senior VP, General Counsel, Corporate Secretary & Chief Sustainability Officer | 1975 |
| Mr. William A. Geist | President of Protein Sciences Segment | 1969 |
| Dr. Bernie Andruss | Senior Vice President of Bio-Techne Diagnostics Division | — |
| Mr. Dylan Malayter | Senior Vice President of Reagent Solutions Division | — |
| Mr. Steven M. Silverman | Senior Vice President of Customer Experience | — |
| Dr. Peter Schuessler | Senior Vice President of EMEA & Commercial Effectiveness | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 7, 2026
Technical indicators
- RSI 14
- 55.73
- MACD 12/26/9
- 0.08
- EMA 9 of MACD
- 0.09
- MACD histogram
- -0.01
- SMA 50
- $72.48
- Price above SMA 50
- EMA 50
- $72.03
- Price above EMA 50
- SMA 200
- $63.21
- Price above SMA 200
- EMA 200
- $65.27
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 5, 2026. Technical data, not a recommendation.
Analyst views
1 analyst rating
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $73.00
- Average
- $73.00
- High
- $73.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.8 | +12.0 | ||||||||||
| 2022 | -22.8 | +4.4 | +3.1 | -12.4 | -3.4 | -3.7 | +9.1 | -13.4 | -14.7 | +1.1 | +9.9 | -4.1 |
| 2023 | -3.5 | -10.6 | -1.0 | +8.3 | +3.2 | -0.1 | +2.8 | -4.5 | -13.6 | -18.6 | +19.1 | +19.5 |
| 2024 | -8.3 | +7.3 | -5.4 | -8.9 | +5.1 | -8.0 | +13.9 | -10.2 | +11.4 | -5.7 | +0.1 | -5.2 |
| 2025 | +2.9 | -14.3 | -4.2 | -12.2 | -2.5 | +5.8 | +5.1 | -0.5 | +4.1 | +4.4 | +5.3 | -7.8 |
| 2026 | +7.4 | -9.6 | -9.6 | +3.4 | -6.1 | +39.1 | +1.5 | +0.2 | +0.4 | +0.4 | -0.0 |



